Gliknik is located in the thriving downtown Baltimore life sciences community

/in /by

Gliknik is located in the thriving downtown Baltimore life sciences community.

Gliknik is currently a profit-generating company.

/in /by

Gliknik is currently a profit-generating company.

Gliknik has raised $33 million of non-dilutive capital.

/in /by

Gliknik has raised $33 million of non-dilutive capital.

Gliknik has raised $23 million of equity.

/in /by

Gliknik has raised $23 million of equity.

We pride ourselves on our courage in pursuit of new scientific challenges

/in , /by

We pride ourselves on our courage in pursuit of new scientific challenges and our willingness to take on novel, sometimes risky drug discovery research from which larger pharmaceutical companies may shy away.

We have a collegial environment that enables us to coordinate innovative experiments

/in , , /by

We have a collegial environment that enables us to coordinate innovative experiments while not being afraid to try new things or to terminate programs that do not yield desired scientific results.

At Gliknik we are committed to scientific rigor

/in , /by

At Gliknik we are committed to scientific rigor in discovering and developing innovative biologics for individuals with autoimmune diseases and cancer.

David and Scott formed Gliknik based upon their wish

/in /by

David and Scott formed Gliknik based upon their wish to use their medical training to ease human suffering through development of better drugs for people living with cancer and autoimmune diseases.

David and Scott Strome first met each other through their children.

/in /by

David and Scott Strome first met each other through their children.

Ray Schinazi is internationally recognized as one of the

/in /by

Ray Schinazi is internationally recognized as one of the most influential persons in the life science sector because he did pioneering work on several blockbuster drugs.